NICE updates guidance on lateral interbody fusion, supported by NuVasive's XLIF data — 5 insights Featured

Written by  Megan Wood | Monday, 20 March 2017 18:02
Social sharing

The National Institute for Health and Care Excellence, based in the United Kingdom, updated guidance for lateral interbody fusion on March 20, 2017.

Here are five insights:


1. NICE reported evidence proving lateral interbody fusion efficacy is "adequate in quality and quantity."


2. The agency supports the procedure's use, given standard arrangements are made for clinical governance, consent and audit.


3. NICE received peer-reviewed journal articles outlining 14 years of investigation into San Diego-based NuVasive's eXtreme Lateral Interbody Fusion procedure.


4. NICE updated its guidance based on a systematic literature review of more than 200 previously published studies on the XLIF procedure. The studies touch on XLIF's safety profile, rate of fusion and improvements in pain and disability.


5. NuVasive unveiled XLIF in the United States in 2003. The minimally invasive procedure is performed through the side of the body. Surgeons have performed more than 150,000 successful XLIF procedures to date.


More articles on MIS:
Robotic guided MIS vs. open fluoroscopic guided spinal fusion: 5 ways outcomes differ
Inspired Spine's study on minimally invasive direct lateral interbody fusion favorable for outpatient setting: 5 observations
Dr. Solomon Kamson presents 5-year review of full-endoscopic assisted MIS lumbar decompression in outpatient setting: 6 observations

Last modified on Tuesday, 21 March 2017 21:59
© Copyright ASC COMMUNICATIONS 2017. Interested in LINKING to or REPRINTING this content? View our policies here.